All In Biotech

Drug Trial Radar · NCT07513376

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 876 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

876

Planned (sponsor's estimate)

Start

May 4, 2026

Primary completion

Aug 22, 2034

Study completion May 11, 2038

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • IntismeranBiological

    IM injection

  • Pembrolizumab coformulated with berahyaluronidase alfaBiological

    SC injection

  • PlaceboOther

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm CTime frame: Up to approximately 98 months

Locations

129 sites in 20 countries. Site status is shown where the registry gives one.

  • UC Davis Comprehensive Cancer Center ( Site 3204)

    Sacramento, California · Recruiting

  • University of Colorado Cancer Center ( Site 3268)

    Aurora, Colorado · Recruiting

  • Smilow Cancer Center at Yale-New Haven ( Site 3253)

    New Haven, Connecticut · Recruiting

  • UF Health Cancer Center ( Site 3257)

    Gainesville, Florida · Recruiting

  • Illinois Cancer Care ( Site 7000)

    Peoria, Illinois · Recruiting

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9509)

    Ypsilanti, Michigan · Recruiting

  • Washington University School of Medicine ( Site 3279)

    St Louis, Missouri · Recruiting

  • Billings Clinic ( Site 3255)

    Billings, Montana · Recruiting

  • NHO Revive Research Institute, LLC ( Site 3218)

    Lincoln, Nebraska · Recruiting

  • Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207)

    Reno, Nevada · Recruiting

  • New York Oncology Hematology, P.C. ( Site 9000)

    Albany, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 3296)

    New York, New York · Recruiting

  • SUNY Upstate Medical University ( Site 3270)

    Syracuse, New York · Recruiting

  • White Plains Hospital ( Site 3213)

    White Plains, New York · Recruiting

  • Charles George VA Medical Center ( Site 3233)

    Asheville, North Carolina · Recruiting

  • UNC Lineberger Comprehensive Cancer Center ( Site 3250)

    Chapel Hill, North Carolina · Recruiting

  • WakeMed Raleigh Campus ( Site 3214)

    Raleigh, North Carolina · Recruiting

  • Sanford Fargo Medical Center ( Site 3236)

    Fargo, North Dakota · Recruiting

  • Altru Health System ( Site 3254)

    Grand Forks, North Dakota · Recruiting

  • Perelman Center for Advanced Medicine ( Site 3205)

    Philadelphia, Pennsylvania · Recruiting

  • Sanford Cancer Center ( Site 3266)

    Sioux Falls, South Dakota · Recruiting

  • Avera Cancer Institute ( Site 3209)

    Sioux Falls, South Dakota · Recruiting

  • The University of Tennessee Medical Center ( Site 3223)

    Knoxville, Tennessee · Recruiting

  • University of Texas-MD Anderson Cancer Center ( Site 3283)

    Houston, Texas · Recruiting

  • Hematology Oncology Associates of Fredericksburg ( Site 3275)

    Fredericksburg, Virginia · Recruiting

  • Fred Hutchinson Cancer Center ( Site 3202)

    Seattle, Washington · Recruiting

  • West Virginia University ( Site 3237)

    Morgantown, West Virginia · Recruiting

  • Gundersen Health System ( Site 3200)

    La Crosse, Wisconsin · Recruiting

  • Royal North Shore Hospital ( Site 0502)

    St Leonards, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital ( Site 0503)

    Brisbane, Queensland, Australia · Recruiting

  • One Clinical Research ( Site 0501)

    Nedlands, Western Australia, Australia · Recruiting

  • Hospital Samaritano De Sao Paulo ( Site 3612)

    São Paulo, Brazil · Recruiting

  • Hospital Sírio Libanês ( Site 3611)

    São Paulo, Brazil · Recruiting

  • Hospital de Clínicas de Passo Fundo ( Site 3601)

    Pasos Fundo, Rio Grande do Sul, Brazil · Recruiting

  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2506)

    Hamilton, Ontario, Canada · Recruiting

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503)

    Kingston, Ontario, Canada · Recruiting

  • The Ottawa Hospital Cancer Centre ( Site 2508)

    Ottawa, Ontario, Canada · Recruiting

  • Centre Hospitalier de l'Université de Montréal ( Site 2501)

    Montreal, Quebec, Canada · Recruiting

  • Bradford Hill Norte ( Site 3705)

    Antofagasta, Chile · Recruiting

  • Clínica MEDS La Dehesa ( Site 3708)

    Lo Barnechea, Region M. de Santiago, Chile · Recruiting

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.